# Genetic Correlates of Synergy Mechanisms of Daptomycin Plus Fosfomycin in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus (MRSA)

**Authors:** Warren E. Rose, Selvi C. Ersoy, Wessam Abdelhady, Alan R. Dominguez, Jedidiah Ndam Muyah Manna, Jorge N. Artaza, Reetakshi Mishra, Ahmed M. Elsayed, Richard A. Proctor, Sarah L. Baines, Benjamin P. Howden, Nagendra N. Mishra

PMC · DOI: 10.3390/microorganisms13071532 · Microorganisms · 2025-06-30

## TL;DR

This study explores how combining daptomycin and fosfomycin affects MRSA bacteria, revealing genetic and molecular mechanisms that improve treatment effectiveness.

## Contribution

The study identifies specific genetic mutations and gene expression changes linked to the synergy of daptomycin and fosfomycin in MRSA.

## Key findings

- Mutations in the mprF gene are common in daptomycin-resistant MRSA strains.
- Combination therapy with daptomycin and fosfomycin prevents the emergence of certain mprF mutations.
- Daptomycin plus fosfomycin alters gene expression, including reduced lrgB expression in an infective endocarditis model.

## Abstract

This study elucidates potential genetic determinants and mechanisms involved in the synergistic effects of daptomycin (DAP) + fosfomycin (FOF) combination therapy. Among 33 clinically derived DAP-susceptible (S)/DAP-resistant (R) isogenic strain pairs, mutations in the mprF gene occurred in 30/33 DAP-R strains, including polymorphisms of L826F (33%) or T345A/L/I (15%). Strain variants of DAP-S CB1483 serially passaged in vitro for 10 days in DAP +/− FOF identified a key non-synonymous mutation in mprF (L826F) only in the DAP monotherapy arm. Interestingly, passage in FOF alone or DAP + FOF prevented the emergence of this mprF mutation following 10-day passage. This L826F mprF polymorphism, associated with a “gain-in-function” phenotype, exhibited increased amounts of lysyl-phosphatidylglycerol (L-PG) in the cell membrane (CM). Transcriptomics revealed a relatively modest number (~10) of distinct genes that were significantly up- or downregulated (≥2 log fold) in both the DAP-S and DAP-R strain pairs upon DAP + FOF exposures (vs. DAP or FOF alone). Of note, DAP + FOF decreased expression of lrgAB and sdrE and increased the expression level of fosB. In a rabbit infective endocarditis (IE) model, the DAP-R CB185 strain treated with DAP +/− FOF showed significantly reduced lrgB expression in vegetations compared with DAP treatment alone. Overall, these findings indicate that DAP + FOF therapy impacts MRSA through multiple specific mechanisms, enhancing bacterial clearance.

## Linked entities

- **Genes:** Mprf (maternal performance) [NCBI Gene 492910], sdrE (MSCRAMM family adhesin SdrE) [NCBI Gene 66838855], FOSB (FosB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2354], LrgB (uncharacterized protein) [NCBI Gene 840100]
- **Chemicals:** daptomycin (PubChem CID 21585658), fosfomycin (PubChem CID 441029)
- **Diseases:** infective endocarditis (MONDO:0000565)
- **Species:** Staphylococcus aureus (taxon 1280)

## Full-text entities

- **Diseases:** IE (MESH:D004696)
- **Chemicals:** DAP (MESH:D017576), FOF (MESH:D005578), Methicillin (MESH:D008712), L-PG (MESH:C002285), CB1483 (-)
- **Species:** Staphylococcus aureus (species) [taxon 1280], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986]
- **Mutations:** L826F, T345A/L

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12299106/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12299106/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12299106/full.md

---
Source: https://tomesphere.com/paper/PMC12299106